Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
Research ArticleFocus: New Directions in Hemostasis and Coagulation

Thrombotic Microangiopathy (TTP and HUS): Advances in Differentiation and Diagnosis

Margaret Schneider
American Society for Clinical Laboratory Science October 2007, 20 (4) 216-220; DOI: https://doi.org/10.29074/ascls.20.4.216
Margaret Schneider
is hematology/coagulation technologist, William Beaumont Hospital, Royal Oak MI
MS MT (ASCP)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mschneider@twmi.rr.com
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. Margaret Schneider, MS MT (ASCP)⇑
    1. is hematology/coagulation technologist, William Beaumont Hospital, Royal Oak MI
  1. Address for correspondence: Margaret Schneider MS MT (ASCP), hematology/coagulation technologist, William Beaumont Hospital, 35212 Banbury Court, Livonia MI 48152. (248) 478-1044. mschneider{at}twmi.rr.com.
  1. Compare and contrast the clinical symptoms and etiology of TTP and HUS.

  2. Name the enzyme responsible for cleaving ultra large von Willebrand factor molecules.

  3. Describe the clinical manifestations of a deficiency of this enzyme.

  4. Predict the most appropriate course of treatment for a patient with this enzyme deficiency.

Extract

Detection of the proteolytic enzyme ADAMTS-13 may be used to differentiate between the forms of thrombotic micro-angiopathy (TMA), thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS).

Thrombotic microangiopathy (TMA) is a form of systemic thrombosis with microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and microthrombi formation within arterioles and capillaries. One third of patients have hemoglobin values below 6 g/dL. MAHA is a form of anemia characterized by elevated reticulocyte count and serum lactate dehydrogenase (LD), decreased serum haptoglobin, and presence of schistocytes (fragmented erythrocytes) on the peripheral blood film. Most patients have normal prothrombin times (PT), activated partial thromboplastin times (PTT), and thrombin times (TT). When left untreated, patients die from systemic microvascular thrombosis causing cerebral and myocardial infarctions and renal failure. In the case reported by Moschcowitz in 1924, a 16-year-old female died of a form of TMA that included MAHA, petechiae, hemiparesis (partial paralysis) and fever.1 Autopsy findings included hyaline thrombi in the terminal arterioles and capillaries of the heart and kidney.

When a patient presents with symptoms of gastroenteritis including abdominal pain and diarrhea, a significantly decreased platelet count, and schistocytes on the peripheral smear but normal coagulation studies, TMA should be strongly considered. Prompt recognition is important because this condition must be classified as either TTP or HUS. Both disorders present with thrombocytopenia and MAHA. Timely treatment with plasma-exchange is very effective for individuals with TTP while HUS does not respond to the same treatment. The majority of patients with HUS recover normal renal function with only…

ABBREVATIONS: ADAMTS = a disintegrin-like and metal-loprotease domain with thrombospondin type motifs; HUS = hemolytic-uremic syndrome; LD = lactate dehydrogenase; MAHA = microangiopathic hemolytic anemia; PT = prothrombin times; PTT = partial thromboplastin times; TMA = thrombotic microangiopathy; TT = thrombin times; TTP = thrombotic thrombocytopenic purpura; ULVWF = ultra-large VWF; VTEC = verotoxin-producing E coli; VWF = Von Willebrand factor; VWF-cp = VWF-cleaving protease.

    INDEX TERMS
  • ADAMTS-13
  • hemolytic-uremic syndrome
  • microangiopathic hemolytic anemia
  • schistocytes
  • thrombotic microangiopathy
  • thrombotic thrombocytopenic purpura
  1. Compare and contrast the clinical symptoms and etiology of TTP and HUS.

  2. Name the enzyme responsible for cleaving ultra large von Willebrand factor molecules.

  3. Describe the clinical manifestations of a deficiency of this enzyme.

  4. Predict the most appropriate course of treatment for a patient with this enzyme deficiency.

  • © Copyright 2007 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 20 (4)
American Society for Clinical Laboratory Science
Vol. 20, Issue 4
Fall 2007
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Thrombotic Microangiopathy (TTP and HUS): Advances in Differentiation and Diagnosis
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Thrombotic Microangiopathy (TTP and HUS): Advances in Differentiation and Diagnosis
Margaret Schneider
American Society for Clinical Laboratory Science Oct 2007, 20 (4) 216-220; DOI: 10.29074/ascls.20.4.216

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Thrombotic Microangiopathy (TTP and HUS): Advances in Differentiation and Diagnosis
Margaret Schneider
American Society for Clinical Laboratory Science Oct 2007, 20 (4) 216-220; DOI: 10.29074/ascls.20.4.216
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Is There a Genetic Relationship Between Arterial and Venous Thrombosis?
  • Introduction: New Directions in Hemostasis and Coagulation
  • Cross Talk Between the Inflammation and Coagulation Systems
Show more Focus: New Directions in Hemostasis and Coagulation

Similar Articles

Keywords

  • ADAMTS-13
  • hemolytic-uremic syndrome
  • microangiopathic hemolytic anemia
  • schistocytes
  • thrombotic microangiopathy
  • thrombotic thrombocytopenic purpura

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire